Covid-19 roundup: AstraZeneca, Pfizer come under fire for production delays; Moderna considers third booster dose to squash new variants
The vaccine race is shaping up to be much more than just a sprint toward authorization.
A day after Merck dropped out entirely, controversies are simmering around AstraZeneca and Pfizer/BioNTech, J&J says it will come along soon, while Moderna is refueling for the long haul.
With vaccine rollout still in bottlenecks even across wealthy nations that have essentially bought up initial supplies, the emergence of new variants is complicating long-term planning. For latecomers, who must now make critical decisions about their still-experimental programs, questions remain on just what levels of efficacy are good enough — and for whom.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.